CC · XBRL financial data

The Chemours Company financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	4,969	6,345	6,794	6,027	5,782	5,808
Cost of goods and services sold	3,902	4,964	5,178	4,721	4,631	4,906
Gross profit	1,067	1,381	1,616	1,306	1,151	902
Research and development	93	107	118	108	109	108
Selling, general and administrative	527	592	710	1,290	585	799
Total operating expenses	700	705	844	1,551	810	966
Interest expense	210	185	163	208	264	269
Other income (expense)	21	163	70	91	8	26
Income tax expense (benefit)	(40)	68	163	(81)	41	109
Net income (loss)	219	608	578	(238)	86	(386)
Earnings per share, basic USD per share	1.33	3.69	3.72	(1.60)	0.58	(2.57)
Earnings per share, diluted USD per share	1.32	3.60	3.65	(1.60)	0.57	(2.57)
Weighted average shares, basic millions of shares	165	165	155	149	149	150
Weighted average shares, diluted millions of shares	166	169	158	149	150	150

Fiscal years (CC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,105	1,451	1,102	1,203	713	670
Accounts receivable	449	644	509	509	619	562
Inventory	939	1,099	1,404	1,352	1,472	1,569
Total current assets	2,633	3,345	3,214	3,835	3,026	3,001
Property and equipment, net	3,474	3,154	3,171	3,216	3,183	3,078
Right-of-use asset	236	227	240	260	258	271
Goodwill	153	102	102	102	46	46
Total assets	7,082	7,550	7,640	8,251	7,515	7,382
Accounts payable	844	1,162	1,251	1,159	1,142	954
Accrued liabilities	577	325	300	1,058	393	506
Total current liabilities	1,442	1,858	1,891	2,486	1,803	1,686
Long-term debt	4,005	3,724	3,590	3,987	4,054	4,099
Lease liability, non-current	194	179	198	206	194	191
Total liabilities	6,267	6,468	6,533	7,512	6,910	7,131
Retained earnings	1,303	1,746	2,170	1,782	1,718	1,220
Total stockholders' equity	813	1,081	1,107	737	604	250
Total liabilities and equity	7,082	7,550	7,640	8,251	7,515	7,382
Common shares outstanding (cover page) millions of shares	165	160	148	149	149	150

Fiscal years (CC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	219	608	578	(238)	86	(386)
Stock-based compensation	16	34	27	18	15	21
Depreciation and amortization	320	317	291	307	301	340
Net cash from operating activities	807	820	754	556	(633)	264
Purchases of property and equipment	267	277	307	370	360	213
Net cash from investing activities	(234)	220	(284)	(229)	(353)	(206)
Share repurchases	0	173	495	69	—	—
Dividends paid	164	164	154	149	148	78
Net cash from financing activities	(449)	(560)	(685)	172	(36)	(126)
Net change in cash	162	446	(247)	503	(1,044)	(39)

SIC 2800 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2800 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Chemours	671	1,591	158*	150.5M	—	Q2 FY26 10-QJun 30, 2026
Huntsman	359	1,717	not reported	175.3M	—	Q3 FY26 10-QSep 30, 2026
Ingevity	97	314	(14)*	34.4M	7.1 quarters	Q2 FY26 10-QJun 30, 2026
Perimeter Solutions	83	214	(0.7)*	163.7M	126.6 quarters	Q2 FY26 10-QJun 30, 2026
Innospec	252	474	not reported	24.6M	—	Q3 FY26 10-QSep 30, 2026
OLIN	215	1,748	110*	114.0M	—	Q3 FY26 10-QSep 30, 2026
Solstice Advanced Materials	750	1,148	262*	158.8M	—	Q2 FY26 10-QJun 30, 2026
Ecovyst	88	250	34*	109.5M	—	Q2 FY26 10-QJun 30, 2026
Balchem	66	291	70*	31.8M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.